TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NUTRILIPID 20%

SOYBEAN OIL
Cardiovascular Approved 1993-05-28
1
Indication
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-05-28
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: SOYBEAN OIL

NUTRILIPID 20% Approval History

Loading approval history...

What NUTRILIPID 20% Treats

1 FDA approvals

Originally approved for its first indication in 1993 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NUTRILIPID 20% FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Nutrilipid ® 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated. Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.